(HealthDay)—A new topical nail fungus treatment, Jublia, has been approved by the U.S. Food and Drug Administration.
Jublia (efinaconazole) is made by the Canadian company Valeant Pharmaceuticals International Inc., the Associated Press reported Wednesday.
Jublia comes in liquid form and is applied directly to the nail. According to Valeant, FDA approval was based on two studies involving more than 1,600 people with onychomycosis. The findings were published last year in the Journal of the American Academy of Dermatology. Cure rates were about 18 percent for the patients involved in one study, and about 15 percent for those involved in the other.
In a statement, Valeant said it plans to begin marketing Jublia late in 2014.
More information: Health Highlights: June 11, 2014